Pharming Group Secures Japan Approval for Joenja in APDS, Expanding Market and Pediatric Indication
PHAR has more than doubled off its 52-week low of $7.502.
Summary
Pharming Group announced regulatory approval from Japan's Ministry of Health, Labour and Welfare for Joenja (leniolisib) to treat APDS in patients aged 4 years and older, marking a significant market expansion and the first global approval for younger pediatric patients.
Key Events · Product Development and Regulatory · PHAR
-
Joenja Approved in Japan
Japan's Ministry of Health, Labour and Welfare (MHLW) has approved Joenja® (leniolisib) for the treatment of activated PI3K delta syndrome (APDS) in adult and pediatric patients aged 4 years and older.
-
First Treatment for APDS in Japan
This approval makes Joenja the first treatment specifically approved in Japan for APDS, addressing a significant unmet medical need.
-
Global First for Younger Pediatric Patients
This is the first approval of Joenja globally covering children aged 4 to 11 with APDS, expanding the drug's indication to a younger patient population.
-
Based on Positive Phase III Data
The MHLW based its approval on positive Phase III clinical data from multinational and Japanese studies, demonstrating efficacy in reducing lymphadenopathy and increasing naïve B cells.
Analysis · PHAR · Life Sciences
This regulatory approval in Japan for Joenja (leniolisib) is a significant positive development for Pharming Group. It marks the first approved treatment for Activated Phosphoinositide 3-Kinase Delta Syndrome (APDS) in Japan and, notably, the first global approval for children aged 4 to 11 with the disease. This expands the addressable market for Joenja and provides a critical treatment option for patients who previously relied on supportive care. The launch is contingent on pricing agreement, but this approval de-risks a major market entry and is expected to contribute materially to future revenues.
How filings like this one have moved
In the 30 days to Sep 12, 2026, 42.4% of the 495 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.47%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, PHAR was trading at $15.82 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.1B. The 52-week trading range was $7.50 to $21.34. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.